Monoclonal antibodies binding to the CD160 transmembrane isoform
US11186635B2 · kind B2 · utility
0Cited by
15References
14Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 25, 2017 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Oct 25, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.